Targeted AAV Gene Therapies and Second-Generation Chaperone Platforms Redefining Fabry Care
Pioneering transformative gene replacement candidates, long-acting enzyme formulations, and oral chaperone therapeutics is opening a breakthrough clinical chapter in Fabry disease management. Detailed analysis within the Fabry Disease Pipeline Market report highlights how adeno-associated virus (AAV) vector-mediated gene therapies deliver functional alpha-galactosidase A (GLA) genes directly to...
0 Комментарии
0 Поделились